Statin Therapy in Lupus-mediated Atherogenesis: Two Birds with One Stone?

Overview

Journal Ann Rheum Dis

Specialty Rheumatology

Date 2010 Nov 12

PMID 21068103

Citations 11

Authors

Sander I van Leuven

Yanice V Mendez-Fernandez

Erik S Stroes

Paul P Tak

Amy S Major

Affiliations

Soon will be listed here.

Abstract

The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.

Citing Articles

Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.

Biscetti F, Polito G, Rando M, Nicolazzi M, Eraso L, DiMuzio P Int J Mol Sci. 2025; 26(2).

PMID: 39859250 PMC: 11765428. DOI: 10.3390/ijms26020535.

B Cells Dynamic in Aging and the Implications of Nutritional Regulation.

Yu Y, Lu C, Yu W, Lei Y, Sun S, Liu P Nutrients. 2024; 16(4).

PMID: 38398810 PMC: 10893126. DOI: 10.3390/nu16040487.

The Shifting Landscape of Lupus Nephritis Management: A Review.

Bankole A, Nwaonu J Cureus. 2022; 14(1):e20950.

PMID: 35154930 PMC: 8815326. DOI: 10.7759/cureus.20950.

Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis.

Ohmura K, Kato M, Watanabe T, Oku K, Bohgaki T, Horita T Arthritis Res Ther. 2018; 20(1):72.

PMID: 29665863 PMC: 5905171. DOI: 10.1186/s13075-018-1589-9.

Immune modulatory effects of statins.

Zeiser R Immunology. 2018; 154(1):69-75.

PMID: 29392731 PMC: 5904709. DOI: 10.1111/imm.12902.

References

McCullough P, Chinnaiyan K . Annual progression of coronary calcification in trials of preventive therapies: a systematic review. Arch Intern Med. 2009; 169(22):2064-70. DOI: 10.1001/archinternmed.2009.382. View

Ferreira G, Navarro T, Telles R, Andrade L, Sato E . Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford). 2007; 46(10):1560-5. DOI: 10.1093/rheumatology/kem186. View

Shimazu H, Kinoshita K, Hino S, Yano T, Kishimoto K, Nagare Y . Effect of combining ACE inhibitor and statin in lupus-prone mice. Clin Immunol. 2010; 136(2):188-96. DOI: 10.1016/j.clim.2010.03.008. View

Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R . Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus. 2003; 12(8):607-11. DOI: 10.1191/0961203303lu429oa. View

Hak A, Karlson E, Feskanich D, Stampfer M, Costenbader K . Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum. 2009; 61(10):1396-402. PMC: 2909444. DOI: 10.1002/art.24537. View

Costenbader K, Liang M, Chibnik L, Aizer J, Kwon H, Gall V . A pravastatin dose-escalation study in systemic lupus erythematosus. Rheumatol Int. 2007; 27(11):1071-7. DOI: 10.1007/s00296-007-0341-6. View

Ferreira G, Teixeira A, Sato E . Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus. 2010; 19(8):927-34. DOI: 10.1177/0961203310364400. View

Bruce I, Urowitz M, Gladman D, Hallett D . Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol. 1999; 26(10):2137-43. View

Sandborg C, Ardoin S, Schanberg L . Therapy Insight: cardiovascular disease in pediatric systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2008; 4(5):258-65. DOI: 10.1038/ncprheum0789. View

10.

Graham K, Lee L, Higgins J, Steinman L, Utz P, Ho P . Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus. Arthritis Rheum. 2008; 58(7):2098-104. PMC: 4143381. DOI: 10.1002/art.23605. View

11.

El-Magadmi M, Bodill H, Ahmad Y, Durrington P, Mackness M, Walker M . Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation. 2004; 110(4):399-404. DOI: 10.1161/01.CIR.0000136807.78534.50. View

12.

Rahman P, Aguero S, Gladman D, Hallett D, Urowitz M . Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus. 2001; 9(9):672-5. DOI: 10.1191/096120300669204787. View

13.

Costenbader K, Karlson E, Gall V, de Pablo P, Finckh A, Lynch M . Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus. Arthritis Rheum. 2005; 53(5):718-23. DOI: 10.1002/art.21441. View

14.

van Leuven S, Franssen R, Kastelein J, Levi M, Stroes E, Tak P . Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford). 2007; 47(1):3-7. DOI: 10.1093/rheumatology/kem202. View

15.

Petri M, Perez-Gutthann S, Spence D, Hochberg M . Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992; 93(5):513-9. DOI: 10.1016/0002-9343(92)90578-y. View

16.

Greenwood J, Steinman L, Zamvil S . Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006; 6(5):358-70. PMC: 3842637. DOI: 10.1038/nri1839. View

17.

Akdim F, van Leuven S, Kastelein J, Stroes E . Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?. Curr Pharm Des. 2007; 13(10):1003-12. DOI: 10.2174/138161207780487548. View

18.

Kotyla P, Sliwinska-Kotyla B, Kucharz E . Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. J Rheumatol. 2006; 33(11):2361-3. View

19.

Woo J, Lin Z, Navab M, Van Dyck C, Trejo-Lopez Y, Woo K . Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis. Arthritis Res Ther. 2010; 12(3):R93. PMC: 2911877. DOI: 10.1186/ar3020. View

20.

Esdaile J, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R . Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001; 44(10):2331-7. DOI: 10.1002/1529-0131(200110)44:10<2331::aid-art395>3.0.co;2-i. View